Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Adolfo De la Fuente"'
Autor:
Yu-Hung Wang, Adrián Mosquera Orgueira, Chien-Chin Lin, Chi-Yuan Yao, Min-Yen Lo, Cheng-Hong Tsai, Adolfo de la Fuente Burguera, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract The European Leukemia Net recommendations provide valuable guidance in treatment decisions of patients with acute myeloid leukemia (AML). However, the genetic complexity and heterogeneity of AML are not fully covered, notwithstanding that ge
Externí odkaz:
https://doaj.org/article/6ead356802e74eccaafc335f241b2a39
Autor:
Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos
Publikováno v:
Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)
Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed
Externí odkaz:
https://doaj.org/article/9c1db4405e274742a000602740ddeff0
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/5b644d52caf6407c83da3785ab40f5bd
Autor:
Mar Tormo, Marina Diaz-Beya, Paola Beneit, Ainhoa Fernández Moreno, Montserrat Arnan, Ana Garrido Diaz, Susana Vives, Maria García Fortes, Antonia Sampol, Jorge Labrador, Antonio Garcia-Guiñon, Carmen Botella, Juan Miguel Bergua Burgues, Mayte Olave, Maria Luz Amigo, Xavier Ortín, Ferrand Ferran Vall-Llovera, Maria Pereiro, Josefina Serrano, Maria Jose Sayas Lloris, Almudena De Laiglesia Lorenzo, Juan Jose Bargay Lleonart, Maria Luisa Calabuig Muñoz, Adolfo De La Fuente
Publikováno v:
HemaSphere, Vol 7, p e4025574 (2023)
Externí odkaz:
https://doaj.org/article/94b6da21d4b64549a1fd78634dbb7199
Autor:
Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D. Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos, Christian Récher
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 7, Pp 1-8 (2022)
Abstract In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival.
Externí odkaz:
https://doaj.org/article/a79de68b14424fe89380e50d0b454990
Autor:
Adrián Mosquera Orgueira, Andrés Peleteiro Raíndo, José Ángel Díaz Arias, Beatriz Antelo Rodríguez, Mónica López Riñón, Claudio Cerchione, Adolfo de la Fuente Burguera, Marta Sonia González Pérez, Giovanni Martinelli, Pau Montesinos Fernández, Manuel Mateo Pérez Encinas
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Risk stratification in acute myeloid leukemia (AML) has been extensively improved thanks to the incorporation of recurrent cytogenomic alterations into risk stratification guidelines. However, mortality rates among fit patients assigned to low or int
Externí odkaz:
https://doaj.org/article/5aede6c8b7c54ba38df284fa7e1db4fd
Autor:
Julio García-Suárez, Javier de la Cruz, Ángel Cedillo, Pilar Llamas, Rafael Duarte, Víctor Jiménez-Yuste, José Ángel Hernández-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sánchez-Godoy, Pilar Martínez-Barranco, Blanca Colás-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrián Alegre, Alberto Velasco, Arturo Matilla, María Concepción Aláez-Usón, Rafael Martos-Martínez, Carmen Martínez-Chamorro, Keina Susana-Quiroz, Juan Francisco Del Campo, Adolfo de la Fuente, Regina Herráez, Adriana Pascual, Elvira Gómez, Jaime Pérez-Oteyza, Elena Ruiz, Arancha Alonso, José González-Medina, Lucía Núñez Martín-Buitrago, Miguel Canales, Isabel González-Gascón, María Carmen Vicente-Ayuso, Susana Valenciano, María García Roa, Pablo Estival Monteliu, Javier López-Jiménez, Cristián Escolano Escobar, Javier Ortiz-Martín, José Luis Diez-Martin, Joaquín Martinez-Lopez, the Asociación Madrileña de Hematología y Hemoterapia (AMHH)
Publikováno v:
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-12 (2020)
Abstract Background Patients with cancer have been shown to have a higher risk of clinical severity and mortality compared to non-cancer patients with COVID-19. Patients with hematologic malignancies typically are known to have higher levels of immun
Externí odkaz:
https://doaj.org/article/a3adfa6f2a6e43bc89a85fd388a33caa
Autor:
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian, Antonio Curti
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
In the past few years, our improved knowledge of acute myeloid leukemia (AML) pathogenesis has led to the accelerated discovery of new drugs and the development of innovative therapeutic approaches. The role of the immune system in AML development, g
Externí odkaz:
https://doaj.org/article/a6e56f3f011e4e9596bb57c9ced75c4c
Autor:
Gilberto I. Barranco, Sara Fernández, Raquel Oña, Julia González-Rincón, Angel Martínez-Ramírez, Ana Teijo, Francisca I. Camacho, Fernando J. Pinedo, Margarita Sánchez-Beato, Lucia Pedrosa, Adolfo de la Fuente, Mónica Estévez, Rebeca Iglesias, Carlos Montalbán, Juan F. García
Publikováno v:
Haematologica, Vol 104, Iss 7 (2019)
Externí odkaz:
https://doaj.org/article/ce9e9d39f87345688b6b34d521011610
Autor:
Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1, Pp e2019016-e2019016 (2019)
BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remissio
Externí odkaz:
https://doaj.org/article/81b4fa5b2a224f32948fabdc5eced125